Skip to main content

This site is dedicated to the products & services provided by Leyden Delta B.V.

Supporting the use of Zaponex® (clozapine) for the management of Treatment-Resistant Schizophrenia (TRS) within mental health services in the UK.

Products

Zaponex (Clozapine)
Orodispersible Tablets

Leyden Delta is the first UK clozapine supplier to introduce an orodispersible clozapine formulation.

Learn More

Zaponex (Clozapine)
Tablets

Zaponex tables are available in 25mg and 100mg tablets and are packaged in either blister packs or HDPE containers for your convenience.

Learn More

Services

ZTAS
Treatment Access System

A secure, comprehensive web-accessed patient database which can be accessed by registered healthcare professionals all year round.

Learn More

Magna Laboratories

Magna Laboratories is the UK-based sister company of Leyden Delta based in Herefordshire.
Learn More

Medical Educational Goods & Services

Magna Laboratories is the UK-based sister company of Leyden Delta based in Herefordshire.
Learn More

News & Updates

Zaponex ODT Tablet Updates
November 24, 2020

Zaponex Orodispersible Tablet Price Reduction

Dear  Healthcare colleague,  Leyden Delta brought to market the first and only orodispersible clozapine tablet in the UK and has recently reviewed the prices of Zaponex (clozapine) Orodispersible tablets. As a result,  the new list prices* are as follows: *List…
ZTAS Updates
November 3, 2020

ZTAS service during the Christmas and New Year period 2020-2021

During the Christmas and New Year’s holiday season, the ZTAS office will be open on weekdays during normal office hours (8.30 am until 5.00 pm), except for the following: CLOSED on Friday 25th December 2020, and Friday 01st January 2021 The office will be closed…
Zaponex ODT Tablet Updates
July 29, 2020

Update to Zaponex Orodispersible Tablet Product Information

Please be informed of a recent update to the product information for Zaponex 12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg orodispersible tablets. Zaponex ODT Summary of Product Characteristics (SPC): Section 6.3: Extension of the shelf life…

Report Side Effects

Yellow Card Scheme

Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Yellow Card Scheme

ZTAS

Adverse events should also be reported to ZTAS.
T: (0207)365 58 42  |  F: (0207)365 58 43  |  E: info@ztas.co.uk
ZTAS